{"id":"gsk217744","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in conditions characterized by immune dysregulation. The drug was developed to provide anti-inflammatory effects with potentially improved tolerability compared to earlier PDE4 inhibitors.","oneSentence":"GSK217744 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:39:54.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"}]},"trialDetails":[{"nctId":"NCT01453998","phase":"PHASE2","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-14","conditions":"Acellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b","enrollment":657},{"nctId":"NCT01248884","phase":"PHASE2","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":"Tetanus, Poliomyelitis, Hepatitis B","enrollment":721}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK217744","genericName":"GSK217744","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK217744 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}